Bengaluru, June 16 -- One of India's largest drugmaker shares slipped on Monday, June 16, after the US Food and Drug Administration (US FDA) issued eight observations on the pharma player's Halol manufacturing facility in Gujarat.

With a market capitalization of Rs 4,02,129, the share price of Sun Pharmaceutical Industries Ltd was trading almost 2% down to Rs 1,655 from its previous closing price of Rs 1,688.

Sun Pharma, in a regulatory filing, said the US FDA conducted a Good Manufacturing Practices (GMP) inspection at its Halol facility between June 2 and June 13, 2025. The inspection concluded with the issuance of a Form 483 containing eight observations, pointing to possible procedural or documentation issues requiring corrective ac...